茯苓酸
分析標(biāo)準(zhǔn)品,HPLC≥97%
Pachymic acid
CAS號：29070-92-6
分子式：C33H52O5
分子量：528.77
MDL：MFCD00238657
別名：茯苓酸.茯靈酸;3-ACETYLTUMULOSIC ACID; Pachymasaeure; pachymaic acid; Lanost-8-en-21-oic acid,3-(acetyloxy)-16-hydroxy; pachimic acid; 3-O-Acetyltumulosic acid; Lanost-8-en-21-oic acid,3-(acetyloxy)-16-hydro
貨號 | 規(guī)格/參數(shù)/品牌 | 價(jià)格 | 貨期 |
YJ-B20400-5mg | 分析標(biāo)準(zhǔn)品,HPLC≥97% | ￥1300.00 | 現(xiàn)貨 |
YJ-B20400-20mg | 分析標(biāo)準(zhǔn)品,HPLC≥97% | ￥3580.00 | 現(xiàn)貨 |
YJ-B27710-5mg | 分析標(biāo)準(zhǔn)品,HPLC≥95% | ￥1100.00 | 現(xiàn)貨 |
YJ-B27710-20mg | 分析標(biāo)準(zhǔn)品,HPLC≥95% | ￥2300.00 | 現(xiàn)貨 |
產(chǎn)品介紹
熔點(diǎn)：296-297℃
沸點(diǎn)：612.2℃ at 760 mmHg
比旋光度：(Py)+17.7
外觀：白色針晶粉末
溶解性：易溶于吡啶
儲(chǔ)存條件：2-8℃
注意：部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶參考交流研究之用。
從2011年開始我們致力于在生命科學(xué)領(lǐng)域、生物醫(yī)學(xué)實(shí)驗(yàn)技術(shù)及論文潤色服務(wù)，協(xié)助客戶各類實(shí)驗(yàn)服務(wù)及論文潤色十多年，是您值得信賴的科研合作伙伴!
如果您受時(shí)間、試驗(yàn)條件等限制而無法完成您的課題研究，歡迎您與我們聯(lián)系。
實(shí)驗(yàn)技術(shù)服務(wù)：
實(shí)驗(yàn)室代做實(shí)驗(yàn)項(xiàng)目
| |||
細(xì)胞熒光染料標(biāo)記檢測實(shí)驗(yàn)
| |||
| |||
染色質(zhì)免疫沉淀分析(CLIP)實(shí)驗(yàn)服務(wù)
| |||
| |||
|
參考文獻(xiàn)(17篇)
17. [IF=5.4] Lihua Cui et al."Hu Gan Tang ameliorates metabolic-associated fatty liver disease by inhibiting ferroptosis through the Nrf2/GPX4 pathway."JOURNAL OF ETHNOPHARMACOLOGY.2025 Sep;353:120342
16. [IF=4] Haotian Yang et al."Poria acid inhibit the growth and metastasis of renal cell carcinoma by inhibiting the PI3K/akt/NF-κb signaling pathway."Heliyon".2024 May;10:
15. [IF=2.751] Zhi-Sen Pan et al."Pachymic acid modulates sirtuin 6 activity to alleviate lipid metabolism disorders."Experimental and Therapeutic Medicine.2023 Jul;26(1):1-9
14. [IF=5.561] Shiqi Chen et al."Optimization of Ultrasonic-Assisted Extraction Conditions for Bioactive Components and Antioxidant Activity of Poria cocos (Schw.) Wolf by an RSM-ANN-GA Hybrid Approach."Foods.2023 Jan;12(3):619
13. [IF=1.496] Yuanyuan Luo et al."Pachymic Acid Inhibits the Migration and Epithelial–Mesenchymal Transition of Renal Cell Carcinoma."Natural Product Communications
12. [IF=5.168] Pan Wang et al."Discovery and characterization of novel ATP citrate lyase inhibitors from natural products by a luminescence-based assay."CHEMICO-BIOLOGICAL INTERACTIONS.2022 Nov;367:110199
11. [IF=2.091] Zhenhong Liu et al."GAPT regulates cholinergic dysfunction and oxidative stress in the brains of learning and memory impairment mice induced by scopolamine."Brain Behav. 2020 May;10(5):e01602
10. [IF=3.512] Binbin Wang et al."Comprehensive Quality Assessment of Kaixin Powder by HPLC–DAD Quantification and HPLC–QTOF-MS/MS Confirmation."Acs Omega. 2021;6(17):11319–11326
9. [IF=5.34] Shangmin Yu et al."nNovel insights into antidepressant mechanism of Kai Xin San formula: inhibiting NLRP3 inflammasome activation by promoting autophagy."Phytomedicine. 2021 Oct;:153792
8. Liu, Zhenhong, et al. "GAPT regulates cholinergic dysfunction and oxidative stress in the brains of learning and memory impairment mice induced by scopolamine." Brain and behavior 10.5 (2020): e01602.https:##doi.org/10.1002/brb3.1602
7. 趙秋龍,卞曉坤,錢大瑋,宿樹蘭,郭盛,王團(tuán)結(jié),段金廒.桂枝茯苓膠囊在原發(fā)性痛經(jīng)模型大鼠血漿、膽汁、尿液和糞便中的代謝產(chǎn)物研究[J].藥物分析雜志,2021,41(01):51-63.
6. 董建設(shè), 趙俊峰, 張林超,等. 茯苓酸通過Wnt信號通路對腎癌細(xì)胞生物學(xué)特性的影響[J]. 中國老年學(xué)雜志, 2019, 39(09):198-201.
5. 于斌, 朱文學(xué), 白喜婷,等. 茯苓浸膏超聲強(qiáng)化干燥工藝優(yōu)化[J]. 食品研究與開發(fā), 2018(1):74-79.
4. 蘭新財(cái), 吳葉鋒, 王麥利,等. 茯苓活性成分提取工藝優(yōu)化[J]. 中國獸藥雜志, 2015, 49(1):14-18.
3. 蔡丹鳳, 陳丹紅. 松蔸栽培茯苓主要營養(yǎng)成分的累積特性[J]. 中華中醫(yī)藥雜志, 2018, 033(001):373-375.
2. 杜方平, 陳衛(wèi)東, 朱月健,等. 大別山區(qū)仿野生栽培茯苓中茯苓多糖和茯苓酸含量研究[J]. 安徽醫(yī)藥, 2015, 19(009):1681-1683.
1. 吳雯 吳銳楓 康江麗. 參苓健體粉指紋圖譜和含量測定方法的研究[J]. 中國藥師 2019 22(05):852-856.
